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*(D Astuti and C J Ricketts contributed equally to this work)AbstractGermline mutations in the von Hippel–Lindau disease (VHL) and succinate dehydrogenase
subunit B (SDHB) genes can cause inherited phaeochromocytoma and/or renal cell carcinoma
(RCC). Dysregulation of the hypoxia-inducible factor (HIF) transcription factors has been linked to
VHL and SDHB-related RCC; both HIF dysregulation and disordered function of a prolyl
hydroxylase domain isoform 3 (PHD3/EGLN3)-related pathway of neuronal apoptosis have been
linked to the development of phaeochromocytoma. The 2-oxoglutarate-dependent prolyl
hydroxylase enzymes PHD1 (EGLN2), PHD2 (EGLN1) and PHD3 (EGLN3) have a key role in
regulating the stability of HIF-a subunits (and hence expression of the HIF-a transcription factors).
A germline PHD2 mutation has been reported in association with congenital erythrocytosis and
recurrent extra-adrenal phaeochromocytoma. We undertook mutation analysis of PHD1, PHD2
and PHD3 in two cohorts of patients with features of inherited phaeochromocytoma (nZ82) and
inherited RCC (nZ64) and no evidence of germline mutations in known susceptibility genes.
No confirmed pathogenic mutations were detected suggesting that mutations in these genes are
not a frequent cause of inherited phaeochromocytoma or RCC.Endocrine-Related Cancer (2011) 18 73–83Endocrine-Related Cancer (2011) 18 73–83
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D Astuti, C J Ricketts et al.: Mutation analysis of HIF prolyl hydroxylasesIntroduction
Germline mutations in the von Hippel–Lindau (VHL)
tumour suppressor gene and in the B, C and D subunits
of succinate dehydrogenase (SDHB, SDHC and
SDHD) are strongly linked with susceptibility to
phaeochromocytoma (Latif et al. 1993, Crossey et al.
1995, Woodward et al. 1997, Baysal et al. 2000, Gimm
et al. 2000, Astuti et al. 2001a,b, Neumann et al. 2002,
Schiavi et al. 2005, Mannelli et al. 2007). In addition,
germline mutations in VHL, SDHB and SDHD are
associated with susceptibility to renal cell carcinoma
(RCC), though the risk of RCC is about five times
higher in VHL disease (Maher et al. 1990, Latif et al.
1993, Vanharanta et al. 2004, Ong et al. 2007, Ricketts
et al. 2008, 2010). Several mechanisms have been
implicated in the development of VHL-related and
SDHB/D-related phaeochromocytomas. The VHL
tumour suppressor gene product (pVHL) has multiple
functions (see Frew & Krek 2007 references within)
but its best-characterised function is the ability to
regulate proteasomal degradation of hypoxia-inducible
factor (HIF)-1a and HIF-2a (Maxwell et al. 1999), and
overexpression of HIF-2a in a RCC cell line counter-
acts pVHL tumour suppressor activity (Kondo et al.
2003). Inactivation of SDHB/D has been linked to
accumulation of succinate that inhibits the prolyl
hydroxylase enzymes necessary for proteasomal
degradation of HIF-a subunits (Selak et al. 2005);
phaeochromocytomas from patients with germline
VHL, SDHB and SDHD mutations demonstrate
up-regulation of HIF-1a and HIF-2a and their down-
stream targets (Pollard et al. 2006). Although HIF
dysregulation and a pseudohypoxic state are features of
both VHL- and SDHB/D-associated tumours, another
potential mechanism for phaeochromocytoma suscept-
ibility in these disorders is a failure of normal prolyl
hydroxylase domain isoform 3 (PHD3) (EGLN3)-
dependent developmental apoptosis of sympathetic
neuronal cells causing persistence of ‘phaeochromo-
cytoma precursor cells’ (Lee et al. 2005). This latter
process has also been linked to other phaeochromo-
cytoma susceptibility disorders (multiple endocrine
neoplasia type 2 and neurofibromatosis) (Lee et al. 2005).
In normoxia, the HIF-1 and HIF-2 a-subunits are
rapidly ubiquitylated and targeted for proteasomal
degradation by a pVHL containing E3 ubiquitin ligase
complex (Maxwell et al. 1999). The oxygen-dependent
interaction of pVHL with HIF-a is determined by the
hydroxylation status of key HIF-a proline residues
(Pro-402 and Pro-564 in HIF-1a) (Ivan et al. 2001,
Jaakkola et al. 2001, Masson et al. 2001, Yu et al.
2001): non-hydroxylated HIF-a binds to pVHL74approximately a 100-fold less tightly than hydroxyl-
ated HIF-a (Chan et al. 2002). Thus in the presence of
oxygen, HIF-a hydroxylation is catalysed by prolyl
hydroxylases that are members of the egg-laying-
defective nine (EGLN) family (Bruick & McKnight
2001, Epstein et al. 2001). Under hypoxic conditions,
the rate of prolyl hydroxylation, and hence the rate
of proteasomal degradation of HIF-a, slows because
pVHL binds only very weakly to the HIF-a subunits
leading to stabilisation of HIF-1 and HIF-2 hetero-
dimeric transcription factors and activation of the array
of genes involved in the hypoxic response. In humans,
three EGLN homologues have been implicated in
HIF-a modification: PHD1/EGLN2/HIFPH1, PHD2/
EGLN1/HIFPH2 and PHD3/EGLN3/HIFPH3 (Bruick
& McKnight 2001, Epstein et al. 2001). To date,
germline mutations in PHD2 have been associated
with congenital polycythaemia and, in one case/family,
recurrent extra-adrenal phaeochromocytoma (Percy
et al. 2006, 2007, Al-Sheikh et al. 2008, Ladroue
et al. 2008). We hypothesised that patients with
features of inherited susceptibility to phaeochromo-
cytoma and/or RCC might harbour germline mutations
in PHD1, PHD2 or PHD3. To test this hypothesis, we
analysed two large patient cohorts without mutations
in known susceptibility genes.Materials and methods
Patients and samples
We analysed DNA from a) 82 individuals with features
of inherited phaeochromocytoma (extra-adrenal
tumours in 23 cases) susceptibility (i.e. familial
phaeochromocytoma (nZ6), multiple tumours
(nZ30) or young age at onset (diagnosed age 30
years or less, range 5–30 years, median 19 years
(nZ46)) but no detectable mutations in VHL, SDHB,
SDHD or RET and b) 64 patients with features of
RCC susceptibility (25 probands from familial RCC
kindreds, 14 individuals with bilateral or multicentric
RCC and 25 individuals with isolated unilateral early-
onset RCC (diagnosis aged 40 years or less; range
17–40 years, median 28 years)) but no evidence of a
germline mutation in a known RCC susceptibility gene
(VHL, SDHB, FH and FLCN) (most cases had clear cell
RCC) (Ricketts et al. 2008, Woodward et al. 2008).
Molecular genetic analyses
Mutation analysis of HIF prolyl hydroxylases
(PHD/EGLN1–3)
PHD1/EGLN2 (exons 1–5), PHD2/EGLN1 (exons 1–5)
and PHD3/EGLN3 (exons 1–5) (see Figure 1) werewww.endocrinology-journals.org
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Figure 1 Schematic representation of the exon structure and location of genetic variants detected in PHD1, PHD2 and PHD3.
The coding sequences for the PHD genes were obtained from Ensembl (http://www.ensembl.org/index.html), and protein domain
annotations were obtained from the UniProt database (http://www.uniprot.org/).
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preamplified using GenomiPhi DNA amplification kit
(GE Healthcare, Chalfont St. Giles, Buckinghamshire,
UK) according to the manufacturer’s instructions, and
0.2 ml of GenomiPhi amplified DNA was used for PCR
amplification. The PCR conditions were as follows:
95 8C for 15 min followed by 35 cycles of 95 8C,
55–58 8C and 72 8C for 30 s each and then 72 8C for
10 min. PCR was performed using HotStarTaq DNA
polymerase (Qiagen). PCR and sequencing were repeated
in the original DNA if sequence variation was observed
in the GenomiPhi amplified DNA. Primer sequences
for exons amplification are available upon request.
CpG methylation analysis of PHD3
PHD3 CpG island methylation analysis was performed
using combined bisulphite and restriction digest analysis
(CoBRA). Sodium bisulphite modification of genomic
DNA was performed using the EpiTect Bisulfite Kit
(Qiagen) according to the manufacturer’s instructions.
PHD3 CpG island was amplified by nested PCR using
primers: PHD3CoF1 50-TTTTGGTTATAAATAATTA-
AGGTTGGYGTYGGGT-30; PHD3CoR1 50-AATAAC-
AAAAACCCACCTCRTACAAACAAA-30;PHD3CoF2
50-TTYGGAGGYGGTTTYGGGGYGGAGTT-30; PHD
3CoR2 50-AAAACATCTCRCCCRCAAAATCRAAA-30.www.endocrinology-journals.orgAll amplification was done using HotStarTaq DNA
polymerase (Qiagen).
Functional analyses of the PHD3-Arg8Ser
mutation
Plasmid construction
The plasmid encoding wild-type PHD3/EGLN3
(pcDNA3-PHD3) has been described previously
(Lee et al. 2005). Mutant PHD3/EGLN3 Arg8Ser was
generated using the QuickChange site-directed muta-
genesis kit (Stratagene, Amsterdam, Netherlands) with
primers 5 0-ACACATCATGAGCCTGGACCTGGAG-
3 0 (forward)and5 0-CTCCAGGTCCAGGCTCATGAT-
GTGT-3 0 (reverse) and verified by DNA sequencing.
PHD3 induced apoptosis assays
Two different apoptosis assays were performed; an
initial method to demonstrate differences and a second,
more sensitive method. The first apoptosis assay
was performed essentially as described by Lee et al.
(2005). Undifferentiated rat PC12 cells were plated
onto collagen-coated 6-well plates and were cotrans-
fected the following day with 500 ng of GFP histone
and either 1 mg of wild-type PHD3, PHD3-Arg8Ser,
PHD3-His196Ala (catalytic dead mutant) or pcDNA3.
Transfection was carried out using Lipofectamine 200075
D Astuti, C J Ricketts et al.: Mutation analysis of HIF prolyl hydroxylases(Invitrogen). Scoring of apoptotic cells (characterised
as having condensed or fragmented nuclei) was done
72 h after transfection. Approximately, 400 cells were
scored for each sample. Samples were blinded and
assays were performed in duplicate.
For the second apoptosis assay, sympathetic neurons
were isolated from the superior cervical ganglia (SCG)
as previously described (Palmada et al. 2002). Briefly,
SCG from Sprague–Dawley rats were isolated at
postnatal day 4 (P4), and sympathetic neurons were
dissociated with 0.25% trypsin and 0.3% collagenase
for 30 min at 37 8C. After dissociation, the neurons
were then cotransfected with GFP and either wild-type
PHD3, PHD3-Arg8Ser, PHD3-His196Ala or pcDNA3
by electroporation on an Amaxa Nucleofector device
as described previously (Kenchappa et al. 2006).
Forty-eight hours later, cells were fixed in 4%
paraformaldehyde (PFA) and stained with DAPI
(Vector Laboratories, Peterborough, UK). The number
of GFP-positive neurons with apoptotic or non-
apoptotic nuclei was counted and w50–80 neurons
were evaluated for each sample. The assay was
performed in triplicate with three different electropora-
tions using different rat litters.
Statistical analysis
Results for the apoptosis assays were compared using
two-tailed Student’s t-tests.Results
Analysis of PHD3
The five exons and flanking sequences of PHD3 were
sequenced in a) 82 patients with features of non-
syndromic inherited phaeochromocytoma suscept-
ibility (i.e. familial phaeochromocytoma, multiple
tumours or young age at onset) but no detectable
mutations inVHL, SDHB, SDHD orRET, b) 22 sporadic
phaeochromocytoma and c) 64 patients with featuresMET/A
ILE VAL PRO
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SER/ SER/
GLY GLY TYR MET ARG L
PHD3/EG
p.R8S c.G
PHD2/EGLN1
p.S289G c.A865G
PHD2/EGLN1
p.S247W c.C740G
PHD1/EGLN2
p.V183M c.G547A
Figure 2 Sequence chromatographs of variants of PHD1, PHD2 a
coding region and amino acid changes. (B) Known variants of PHD1
projects/SNP).
76of RCC susceptibility. Sequence variants identified
in patients were then tested for in normal controls.
A germline missense substitution, c.24GOC
(p.Arg8Ser), was detected in 1 of 82 patients with
features of non-syndromic inherited phaeochromo-
cytoma susceptibility (see Fig. 2A) (but not in 222
control chromosomes). The substitution was predicted
to be benign and tolerated by bioinformatic analysis
with the Polyphen and SIFT programs, and occurred in
the N-terminal region of the protein which, by analogy
with structural and biochemical work on the catalytic
domain of PHD2 (residues 181–426, tPHD2 here-
after), is unlikely to be directly involved in catalysis
(McDonough et al. 2006, Flashman et al. 2008,
Chowdhury et al. 2009; see Figs 1, 3 and
Table 1). The female patient had bilateral adrenal
phaeochromocytomas at age 22. She showed no
clinical evidence of a known familial susceptibility
syndrome and no family history of phaeochromo-
cytoma. The missense substitution was not detected in
her clinically unaffected father and sister, but it was not
possible to determine whether it had arisen de novo
because no DNA was available from her mother who
had died from an unrelated cause. No novel sequence
variants were detected in the 64 patients with RCC
susceptibility.
Previously, wild-type PHD3 has been shown to
induce apoptosis of rat phaeochromocytoma (PC12)
cells and rat sympathetic neurons. To investigate
whether the PHD3 p.Arg8Ser missense substitution
might alter pro-apoptotic activity, PC12 cells and rat
sympathetic neurons were transfected with either
wild-type PHD3, p.Arg8Ser mutant PHD3, empty
vector control or a catalytically inert p.His196Arg
PHD3 mutant (Lee et al. 2005, Schlisio et al. 2008).
For the PC12 cells, a baseline apoptosis rate of 2–4%
was seen with the empty vector and the inert mutant
control, but both wild-type and p.Arg8Ser mutant
PHD3 were associated with an increase in apoptosisB LEU/
EU ALA SER ALA
PHD2/EGLN1
p.Q157H c.G471C
PHD2/EGLN1
p.C127S c.G380C
PHD1/EGLN2
p.S58L c.C173T
rs61750991rs12097901rs61750953
LN3
24C
HIS/
PHE GLN GLU
SER/
PRO CYS ARG
nd PHD3. (A) Novel variants of PHD1, PHD2 and PHD3 with
and PHD2 with SNPdb reference (http://www.ncbi.nlm.nih.gov/
www.endocrinology-journals.org
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Figure 3 Conservation of variants of PHD1, PHD2 and PHD3. Conservation of the PHD genes performed using sequences obtained
from Ensembl (http://www.ensembl.org/index.html) and aligned using clustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html).
Endocrine-Related Cancer (2011) 18 73–83(12.7 and 14% respectively) (data not shown). For the
more sensitive rat sympathetic neuron assay, a similar
baseline apoptosis rate of 3–4% was seen with the
empty vector and the inert mutant control. Again
wild-type and p.Arg8Ser mutant PHD3 were associ-
ated with an increase in apoptosis (30.6 and 22.8%
respectively) that was highly statistically significant
compared to the catalytically inert mutant (PZ0.0001
and PZ0.0003), though the p.Arg8Ser mutant
demonstrated a mildly, yet statistically significant,
lower level of apoptosis (PZ0.016) than that of the
wild type (see Fig. 4).
We also analysed up to 22 sporadic phaeochromo-
cytomas for somatic mutations and for de novo
promoter region methylation of PHD3. No somatic
mutations were detected in 22 tumours, and analysis of
a PHD3 5 0 CpG island (nt K345 to K160 relative to
the ATG start codon; NM 022073.2 Genome Browser
on Human, May 2004 assembly) by CoBRA and
bisulphite sequencing in 17 sporadic phaeochromo-
cytoma tumours demonstrated partial promoter
methylation (that was not detected in matched normal
(blood) tissue) in only one of 17 tumours analysed.Table 1 Bioinformatic analysis of the PHD genes using the PolyPhe
http://sift.jcvi.org/)
Genes AA change PolyPh
PHD1 S58L 1.773
PHD1 V183M 1.361
PHD2 C127S –
PHD2 Q157H 1.538
PHD2 S247W 1.529
PHD2 S289G 0.376
PHD3 R8S 1.297
www.endocrinology-journals.orgAnalysis of PHD2
Of 82 patients with features of phaeochromocytoma
susceptibility, 10 patients (12.2%) had a germline
non-synonymous missense substitution, c.471GOC
(p.Q157H) (see Fig. 2B), but this was also detected
in 3/111 (2.7%) of normal controls (PZ0.017).
A novel missense p.Ser247Trp (c.740 COG)
substitution was detected in a patient with unilateral
RCC at age 55 years and a contralateral RCC at age
56 years (see Fig. 2A). The substitution was not
detected in 222 chromosomes from normal subjects
and occurred in a region of the protein with no
predicted function (see Fig. 1). Bioinformatic analysis
with the Polyphen and SIFT programs suggests that
this is possibly damaging and intolerant, and the S247
residue is conserved down to Danio rerio and Xenopus
tropicalis, but not to Drosophila melanogaster or
Caenorhabditis elegans (Fig. 3 and Table 1). However,
there were no relatives with RCC to test segregation
in the family.
Mutation analysis of 22 sporadic phaeochromo-
cytomas revealed a novel missense variant (p.Ser289Gly;
c.865AOG) in a single tumour (see Fig. 2A). Germlinen and SIFT programs (http://genetics.bwh.harvard.edu/pph/ and
en SIFT
Possibly damaging 0.03 Intolerant
Benign 0.02 Intolerant
Benign 0.00 Intolerant
Possibly damaging 0.00 Intolerant
Possibly damaging 0.03 Intolerant
Benign 0.20 Tolerant
Benign 1.00 Tolerant
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Figure 4 Apoptosis assay of PHD3-Arg8Ser mutant variant.
Rat sympathetic neurons were cotransfected with GFP and
with either wild-type PHD3, PHD3-Arg8Ser, PHD3-His196Ala
or pcDNA3. The number of GFP-positive neurons with
apoptotic nuclei was counted, andw70–100 neurons were
evaluated for each sample from three separate experiments.
Error bars demonstrate S.D., and P values from Student’s t-tests
are shown.
D Astuti, C J Ricketts et al.: Mutation analysis of HIF prolyl hydroxylasesDNA was not available, and the substitution was not
detected in 222 chromosomes from normal subjects.
Structurally informed bioinformatic analysis with the
Polyphen and SIFT programs suggested that this
substitution is likely to be a benign variant, and
Ser289 residue is not conserved in rodents or in
human PHDs (see Fig. 3 and Table 1). Crystallographic
analyses (Chowdhury et al. 2009) reveal that Ser289 is
not involved with the active site (see Figs 1 and 5).Analysis of PHD1
Mutation analysis of PHD1 in 82 patients with
evidence of inherited phaeochromocytoma suscept-
ibility revealed a novel non-synonymous p.Ser58Leu
(c.173COT) germline missense substitution (see
Fig. 2B) in 5 cases (6%) and 3/116 (2.6%) normal
controls (PZ0.29).
A novel missense p.Val183Met (c.547 GOA)
substitution was detected in a patient with familial
RCC (see Fig. 2A). Both the proband and her father
had been affected with RCC in the sixth decade, but
germline DNA was not available from other relatives.
The substitution was not detected in 222 chromosomes
from normal subjects, and bioinformatic analysis gave
conflicting results with Polyphen suggested that this
was a benign substitution but the SIFT program
reporting it to be intolerant (see Table 1). Val183 is
conserved down to D. rerio, but not to D. melanogaster
or C. elegans (see Fig. 3).
No potential pathogenic variants were detected in 22
sporadic phaeochromocytoma tumours.78Discussion
We did not find any evidence that germline mutations
in PHD1, PHD2 or PHD3 are frequent causes of
inherited susceptibility to phaeochromocytoma or
RCC. Thus, although Ladroue et al. (2008) reported
a patient with recurrent paraganglioma and a germline
PHD2 missense mutation (c.1121A/G, p.H374R,
with loss of the wild-type allele in paraganglioma
tissue), our findings suggest that PHD2 mutations are
rare in patients with features of inherited phaeo-
chromocytoma (95% confidence interval 0–4.4%).
PHD2 mutations were initially described in association
with familial erythrocytosis (Percy et al. 2006, 2007,
Al-Sheikh et al. 2008) and that the patient reported by
Ladroue et al. (2008) had both recurrent paragan-
glioma and congenital erythrocytosis. Although it
might be hypothesised that germline PHD2 mutations
might be restricted to phaeochromocytoma patients
with congenital erythrocytosis, we did not identify a
PHD2 mutation in a patient with early onset
phaeochromocytoma and erythrocytosis.
All three PHD isoforms regulate both HIF-1a and
HIF-2a, but differ in expression patterns, specificities
for the two different prolyl hydroxylation sites within
the HIF-1a and 2a subunits, and a degree of selectivity
between HIF-a isoforms (Appelhoff et al. 2004, Raval
et al. 2005). PHD2 appears to be the major regulator of
HIF-a prolyl hydroxylation in normoxia and mild
hypoxia, and we postulated that PHD2 mutations (that
led to HIF dysregulation) might present with inherited
RCC (previously, a similar approach had revealed
unsuspected germline SDHB and FLCN mutations in
w10% of patients with apparently non-syndromic
inherited RCC (Ricketts et al. 2008, Woodward et al.
2008)). Although we detected a novel PHD2 missense
variant (c.840 COG, p.S247W) in a proband with two
independent RCC, the significance of this finding is
uncertain. While the absence of the variant in 222
chromosomes from normal subjects and bioinformatic
analysis were suggestive of pathogenicity (the S247
residue is conserved in D. rerio), we are unable to
prove a loss of function effect. S247 is located in the
variable region (variable with respect to PHD1, PHD2
and PHD3 sequences) between strands b2 and b3
(referred to as ‘b2b3 loop’) in the published crystal
structures of PHD2 (McDonough et al. 2006,
Chowdhury et al. 2009). Subsequent biophysical
analyses have shown that this region is flexible and
involved in determining the prolyl hydroxylation site
selectivity of the PHDs (Villar et al. 2007, Flashman
et al. 2008, Chowdhury et al. 2009). However, a point
mutation at this position (Ser289Lys) that could bewww.endocrinology-journals.org
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Figure 5 Ribbon representation of tPHD2.CODD complex
structure showing the germline mutation sites (highlighted in
white) in PHD2 (Chowdhury et al. 2009). The tPHD2 fold
comprises four a helices and ten b strands of which eight
strands form a double-stranded b helix (DSBH) (McDonough
et al. 2006, Chowdhury et al. 2009). The recognition of HIF-a by
PHDs involves interactions that are discrete from the hydroxy-
lation site involving the b2/b3 loop and the C-terminal a4 helix
among others. Although the b2/b3 loop of PHD2 makes
hydrophobic contacts with the conserved LXXLAP motif,
residue S247 is located on a part of b2/b3 loop that does not
interact with HIF-a. The figure also shows that residues S289,
V199 (analogous to V183 in PHD1) and P187 (analogous to R8
in PHD3) are far from the HIF-a-binding sites or the catalytic
Fe/2OG-binding motifs in PHD2.
Endocrine-Related Cancer (2011) 18 73–83produced in the soluble form was as active as wild-type
PHD2 (in studies using recombinant tPHD2) with
respect to hydroxylation of the peptide fragments of the
N- and C-terminal oxygen-dependent degradation
domains of HIF-1a when these were tested either
separately or simultaneously in competition revealing
that (at least) under standard incubation conditions,
mutations at Ser289 are unlikely to affect absolute
activity or selectivity with respect to the hydroxylation
sites on HIF-a (data not shown).
Distinguishing mutations from non-pathogenic
sequence variants and predicting the functional effect
of rare missense variants on protein function can be
challenging, but while the pathogenicity of the
p.S247W missense substitution cannot be unequivo-
cally established or disproved, our results do suggest
that germline PHD2 mutations are not a frequent cause
of inherited RCC. Similarly, a possible PHD1 missense
mutation (pVal183Met) was detected in only onewww.endocrinology-journals.orgproband with features of non-syndromic inherited
RCC. While this variant was not detected in O200
control chromosomes and the V183 residue is con-
served in D. rerio, bioinformatic predictions of likely
pathogenicity (Polyphen and SIFT programs) were
equivocal and the substitution occurs outside of the
prolyl hydroxylation catalytic domain (AA 189–375).
Functional studies of mutant pVHL protein associ-
ated with differing VHL disease phenotypes (e.g. with
differential risks of RCC and phaeochromocytoma)
suggest that whereas impairment of the ability to
regulate HIF is necessary for predisposition to RCC, it
is not sufficient, and impairment of non-HIF-related
pVHL functions is also required (Clifford et al. 2001).
Hence, mutations that lead only to dysregulation of
HIF (e.g. germline mutations in PHDs, HIF-1 or HIF-2
genes) might not be sufficient to cause an inherited
RCC phenotype. Interestingly, functional analysis of
pVHL mutants has also suggested that some VHL
mutations associated with a high risk of phaeochro-
mocytoma do not compromise pVHL regulation of
HIF, so implicating HIF-independent mechanisms in
the development of VHL-associated phaeochromo-
cytoma (Clifford et al. 2001, Hoffman et al. 2001).
Consistent with this hypothesis, Lee et al. (2005)
described a HIF-independent pathway linked to
inherited causes of phaeochromocytoma (including
those associated with germline VHL, SDHB and SDHD
mutations). They suggested that inherited phaeo-
chromocytomas originate from sympathetic neuronal
precursor cells that usually undergo c-Jun-dependent
apoptosis during embryogenesis when growth
factors such as nerve growth factor (NGF) become
limiting (Estus et al. 1994, Schlingensiepen et al. 1994,
Ham et al. 1995, Xia et al. 1995). Germline VHL and
SDHB mutations compromise this pathway leading to a
failure of normal developmental apoptosis and survival
of cells that would give rise to phaeochromocytoma.
Intriguingly, PHD3 (but not PHD1 or PHD2) is a key
mediator of this apoptotic pathway, and germline
mutations in KIF1BBeta (that encodes a target of
PHD3/EGLN3) have been associated with familial
susceptibility to neural crest tumours (Schlisio et al.
2008). Furthermore, PHD3 knockout mice demon-
strated increased numbers of cells in the superior
cervical ganglion, adrenal medulla and carotid body
(Bishop et al. 2008). However, we identified only one
potential PHD3 mutation in our cohort of inherited
phaeochromocytoma probands and, although the
missense variant was not detected in normal controls,
we did not detect any evidence that the p.Arg8Ser
impaired neuronal apoptosis to a substantial degree (as
compared to a catalytically inert mutant). Although the79
D Astuti, C J Ricketts et al.: Mutation analysis of HIF prolyl hydroxylasespartial loss of functional effect of the p.Arg8Ser mutant
in the sensitive rat sympathetic neuron apoptosis assay
suggests that the variant might contribute to phaeo-
chromocytoma susceptibility, we suggest that germline
PHD3 mutations are not a frequent cause of inherited
phaeochromocytoma. Germline mutations in both VHL
and SDHB/D mutations are important causes of
familial phaeochromocytoma; however, somatic
mutations of these genes are infrequent in sporadic
tumours (Eng et al. 1995, Astuti et al. 2001a,b). Hence,
we concentrated our efforts on testing for germline
PHD1, PHD2 and PHD3 mutations in patients with
features of inherited phaeochromocytoma. In our
preliminary analysis of sporadic phaeochromocytoma,
we did not find any frequent evidence for somatic
inactivation of PHD1, PHD2 or PHD3. In contrast to
phaeochromocytoma, somatic VHL mutations are very
frequent in sporadic RCC (Foster et al. 1994, Gnarra
et al. 1994, Banks et al. 2006) (though somatic SDHB
inactivation is rare in RCC (Morris et al. 2004)).
However, large-scale resequencing of RCC samples
(nZ101) did not detect mutations in PHD1, PHD2 or
PHD3 (Dalgliesh et al. 2010), and we have not
detected frequent evidence of up-regulation of any of
the three prolyl hydroxylase genes in RCC cell lines
treated with 5-azacytidine (Morris et al. 2010 and
unpublished studies). The absence of germline PHD1,
PHD2 or PHD3 mutations in inherited phaeochromo-
cytoma or RCC might suggest that inactivation of one
of these genes is insufficient to replicate the range of
pro-oncogenic effects associated with pathogenic
germline VHL or SDHB/D mutations. pVHL has been
reported to have multiple functions (Frew & Krek
2007), and while inactivation of SDH has been linked
to accumulation of succinate and resulting inhibition of
prolyl hydroxylase enzymes that are necessary for
proteasomal degradation of HIF-a subunits (Selak
et al. 2005), succinate accumulation may also inhibit
other 2-oxoglutarate-dependent enzyme superfamily
members which may also contribute to the develop-
ment of SDHB/D-associated tumours (e.g. histone
demethylases, some of which are implicated in the
epigenetic regulation of oncogenes and tumour
suppressor genes) (Smith et al. 2008). Nevertheless, a
significant fraction of patients with features of
inherited phaeochromocytoma or RCC do not have a
detectable mutation in a known susceptibility gene.
The advent of comprehensive genomic analysis
techniques (e.g. whole exome resequencing) (Kryukov
et al. 2009, Summerer et al. 2010) should expedite the
identification of novel phaeochromocytoma/RCC pre-
disposition genes and so provide further insights into
the mechanism of tumourigenesis in these disorders.80Declaration of interest
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